IGF1R and metastatic neoplasm: In a previous trial testing the IGF-1R antibody figitumumab in combination with endocrine therapy for front line treatment of metastatic disease, patients with normal glucose control as defined by HbA1c less than 5.7% had a trend toward benefit with the addition of figitumumab25.